In preclinical NPM1-mutant AML models, XPO1 inhibition induces rapid downregulation of HOXA9/MEIS1, reprograms lineage-specific transcription, and promotes myeloid differentiation—effects that weaken the blast’s niche adaptation (Falini et al., 2022). The gene discussed is XPO1; the disease is acute myeloid leukemia.